FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115158844> ?p ?o ?g. }

• W2115158844 abstract "Abstract Background We analyzed the responses to first line treatment and clinical outcomes of metastatic breast cancer patients treated with palliative doxorubicin/cyclophosphamide (AC) according to molecular cancer subtype. Methods A retrospective analysis was performed for 110 metastatic breast cancer patients selected on the basis of palliative AC treatment and the availability of immunohistochemical data for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2/neu) status. Results Of the 110 patients analyzed, 71 (64.5%) were hormone receptor positive (HR+), 14 (12.7%) were HER2+, and 25 (22.7%) were triple negative (TN). There were no differences in age, stage at diagnosis, total number of cycles of palliative chemotherapy, incidence of visceral metastasis, and metastatic sites with the exception of liver among breast cancer subtypes. The overall response rates to AC were 55.9% for the HR+ subgroup, 42.9% for the HER2+ subgroup, and 56.5% for the TN subgroup. The progression-free survival (PFS) in patients with HER2+ and TN were significantly shorter than in the HR+ (median PFS, 9.1 vs 8.1 vs 11.5 months, respectively; p = 0.0002). The overall survival (OS) was 25.4 months in the TN subgroup and 27.3 months in HER2+ subgroup. The median OS for these two groups was significantly shorter than for patients in the HR+ subgroup (median, 38.5 months; 95% CI, 30.1-46.9 months; p < 0.0001). Conclusions The response to palliative AC chemotherapy did not differ among breast cancer subtypes. Despite chemosensitivity for palliative AC, the TN subtype has a shorter overall survival than non-TN subtypes. Innovative treatment strategies should be developed to slow the course of disease." @default.
• W2115158844 created "2016-06-24" @default.
• W2115158844 creator A5004951763 @default.
• W2115158844 creator A5006385407 @default.
• W2115158844 creator A5006473082 @default.
• W2115158844 creator A5007089296 @default.
• W2115158844 creator A5012507797 @default.
• W2115158844 creator A5014437816 @default.
• W2115158844 creator A5018142878 @default.
• W2115158844 creator A5043984377 @default.
• W2115158844 creator A5079167039 @default.
• W2115158844 creator A5082025437 @default.
• W2115158844 creator A5085596906 @default.
• W2115158844 creator A5087509589 @default.
• W2115158844 creator A5089465499 @default.
• W2115158844 date "2010-10-05" @default.
• W2115158844 modified "2023-10-17" @default.
• W2115158844 title "Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype" @default.
• W2115158844 cites W1523531555 @default.
• W2115158844 cites W1812227581 @default.
• W2115158844 cites W1828224642 @default.
• W2115158844 cites W1861588860 @default.
• W2115158844 cites W1897371354 @default.
• W2115158844 cites W1946038024 @default.
• W2115158844 cites W1973862691 @default.
• W2115158844 cites W1973881214 @default.
• W2115158844 cites W1974513579 @default.
• W2115158844 cites W1986989859 @default.
• W2115158844 cites W1989663680 @default.
• W2115158844 cites W1995224853 @default.
• W2115158844 cites W1996457137 @default.
• W2115158844 cites W1999463736 @default.
• W2115158844 cites W2003029412 @default.
• W2115158844 cites W2008863543 @default.
• W2115158844 cites W2043409879 @default.
• W2115158844 cites W2048553013 @default.
• W2115158844 cites W2064845103 @default.
• W2115158844 cites W2067380588 @default.
• W2115158844 cites W2083466846 @default.
• W2115158844 cites W2097255042 @default.
• W2115158844 cites W2102596641 @default.
• W2115158844 cites W2124640147 @default.
• W2115158844 cites W2126575569 @default.
• W2115158844 cites W2131994307 @default.
• W2115158844 cites W2136655134 @default.
• W2115158844 cites W2136983579 @default.
• W2115158844 cites W2142460765 @default.
• W2115158844 cites W2143596998 @default.
• W2115158844 cites W2146737728 @default.
• W2115158844 cites W2154142993 @default.
• W2115158844 cites W2156010010 @default.
• W2115158844 cites W2157285286 @default.
• W2115158844 cites W2157840751 @default.
• W2115158844 cites W2161426850 @default.
• W2115158844 cites W2168379483 @default.
• W2115158844 cites W2169073956 @default.
• W2115158844 cites W2170602872 @default.
• W2115158844 cites W431041432 @default.
• W2115158844 doi "https://doi.org/10.1186/1471-2407-10-527" @default.
• W2115158844 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2972282" @default.
• W2115158844 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20920367" @default.
• W2115158844 hasPublicationYear "2010" @default.
• W2115158844 type Work @default.
• W2115158844 sameAs 2115158844 @default.
• W2115158844 citedByCount "10" @default.
• W2115158844 countsByYear W21151588442012 @default.
• W2115158844 countsByYear W21151588442015 @default.
• W2115158844 countsByYear W21151588442016 @default.
• W2115158844 countsByYear W21151588442018 @default.
• W2115158844 countsByYear W21151588442021 @default.
• W2115158844 crossrefType "journal-article" @default.
• W2115158844 hasAuthorship W2115158844A5004951763 @default.
• W2115158844 hasAuthorship W2115158844A5006385407 @default.
• W2115158844 hasAuthorship W2115158844A5006473082 @default.
• W2115158844 hasAuthorship W2115158844A5007089296 @default.
• W2115158844 hasAuthorship W2115158844A5012507797 @default.
• W2115158844 hasAuthorship W2115158844A5014437816 @default.
• W2115158844 hasAuthorship W2115158844A5018142878 @default.
• W2115158844 hasAuthorship W2115158844A5043984377 @default.
• W2115158844 hasAuthorship W2115158844A5079167039 @default.
• W2115158844 hasAuthorship W2115158844A5082025437 @default.
• W2115158844 hasAuthorship W2115158844A5085596906 @default.
• W2115158844 hasAuthorship W2115158844A5087509589 @default.
• W2115158844 hasAuthorship W2115158844A5089465499 @default.
• W2115158844 hasBestOaLocation W21151588441 @default.
• W2115158844 hasConcept C121608353 @default.
• W2115158844 hasConcept C126322002 @default.
• W2115158844 hasConcept C143998085 @default.
• W2115158844 hasConcept C187960798 @default.
• W2115158844 hasConcept C23589133 @default.
• W2115158844 hasConcept C2775930923 @default.
• W2115158844 hasConcept C2776694085 @default.
• W2115158844 hasConcept C2776755627 @default.
• W2115158844 hasConcept C2779013556 @default.
• W2115158844 hasConcept C2780110267 @default.
• W2115158844 hasConcept C2780140570 @default.
• W2115158844 hasConcept C2781303535 @default.
• W2115158844 hasConcept C530470458 @default.
• W2115158844 hasConcept C71924100 @default.
• W2115158844 hasConcept C90924648 @default.

• next